ATE526982T1 - Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen - Google Patents
Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzenInfo
- Publication number
- ATE526982T1 ATE526982T1 AT02719102T AT02719102T ATE526982T1 AT E526982 T1 ATE526982 T1 AT E526982T1 AT 02719102 T AT02719102 T AT 02719102T AT 02719102 T AT02719102 T AT 02719102T AT E526982 T1 ATE526982 T1 AT E526982T1
- Authority
- AT
- Austria
- Prior art keywords
- neuropathic pain
- treat neuropathic
- neublastin polypeptides
- neublastin
- polypeptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Addiction (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82042101A | 2001-03-28 | 2001-03-28 | |
US28755401P | 2001-03-28 | 2001-03-28 | |
PCT/US2002/006388 WO2002078730A2 (en) | 2001-03-28 | 2002-02-28 | Use of neublastin polypeptides for treating neuropathic pain |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE526982T1 true ATE526982T1 (de) | 2011-10-15 |
Family
ID=29552973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02719102T ATE526982T1 (de) | 2001-03-28 | 2002-02-28 | Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1395279B1 (de) |
JP (3) | JP4499362B2 (de) |
CN (1) | CN1525866B (de) |
AR (1) | AR033031A1 (de) |
AT (1) | ATE526982T1 (de) |
AU (1) | AU2002250203B2 (de) |
CA (1) | CA2442159C (de) |
ES (1) | ES2374971T3 (de) |
HK (1) | HK1062805A1 (de) |
MY (1) | MY143470A (de) |
NZ (1) | NZ529126A (de) |
WO (1) | WO2002078730A2 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
GEP20084464B (en) * | 2003-01-31 | 2008-08-25 | Biogen Idec Inc | Mutated neublastin |
CA2864810A1 (en) * | 2003-04-18 | 2004-11-04 | Biogen Idec Ma, Inc. | Polymer-conjugated glycosylated neublastin |
ATE478092T1 (de) | 2003-06-10 | 2010-09-15 | Nsgene As | Verbesserte sekretion von neublastin |
US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
EP1745069B1 (de) | 2004-03-30 | 2009-05-06 | Nsgene A/S | Therapeutische verwendung des wachstumsfaktors nsg33 |
EP1786454B1 (de) * | 2004-08-19 | 2010-07-21 | Biogen Idec MA Inc. | Neublastin-varianten |
EP1784203B1 (de) | 2004-08-19 | 2010-06-30 | Biogen Idec MA Inc. | Rückfaltung von proteinen der transforming-growth-factor-beta-familie |
TWI501774B (zh) * | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
EP2142205B1 (de) | 2007-05-01 | 2014-04-02 | Biogen Idec MA Inc. | Neublastin Peptide für erhöhte Vaskularisierung im Gewebe mit reduzierter Durchblutung |
ES2584068T3 (es) | 2010-10-01 | 2016-09-23 | Nsgene A/S | Uso de meteorina para el tratamiento de alodinia, hiperalgesia, dolor espontáneo y dolor fantasma |
CN104105501B (zh) | 2011-09-05 | 2017-10-20 | 霍巴治疗公司 | 异常性疼痛、痛觉过敏、自发性疼痛、和幻痛的治疗 |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
WO2015042580A1 (en) * | 2013-09-23 | 2015-03-26 | Biogen Idec Ma Inc. | Compositions and methods for treatment of neuropathic pain |
EP3804747A1 (de) * | 2015-01-18 | 2021-04-14 | Gloriana Therapeutics, Inc. | Therapeutische proteinformulierungen |
BR112020014330A2 (pt) * | 2018-01-15 | 2020-12-08 | Lateral IP Pty Ltd | Método de tratamento de dor neuropática em um indivíduo, composição farmacêutica, composição para uso, uso de um peptídeo de fórmula (i), ou um sal farmaceuticamente aceitável deste na manufatura de um medicamento para o tratamento de dor neuropática em um indivíduo, composição analgésica, método de tratamento de uma condição em um indivíduo, e uso de um peptídeo de fórmula (ii), ou um sal farmaceuticamente aceitável deste, na manufatura de um medicamento para o tratamento de dor neuropática em um indivíduo |
WO2022233989A1 (en) | 2021-05-06 | 2022-11-10 | Hoba Therapeutics Aps | Prevention and treatment of chemotherapy-induced neuropathic pain |
CA3239550A1 (en) | 2021-12-10 | 2023-06-15 | Kenneth Petersen | Treatment of nociceptive pain |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
AU661854B2 (en) | 1991-06-27 | 1995-08-10 | Bristol-Myers Squibb Company | CTL4A receptor, fusion proteins containing it and uses thereof |
US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
ES2225819T3 (es) | 1991-09-20 | 2005-03-16 | Amgen Inc. | Factor neurotrofico de origen glial. |
US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
CA2092271C (en) | 1993-03-09 | 2009-10-13 | Eddie Reed | Use of g-csf for treating taxol side-effects |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US5739307A (en) | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
KR100195886B1 (ko) | 1996-11-01 | 1999-06-15 | 김상조 | 당뇨병 치료용 의약조성물 |
US20020055467A1 (en) * | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
IL140877A0 (en) | 1998-07-14 | 2002-02-10 | Janssen Pharmaceutica Nv | Neurotrophic growth factor |
US6284540B1 (en) * | 1998-09-29 | 2001-09-04 | Washington University | Artemin, a novel neurotrophic factor |
JP2002531128A (ja) * | 1998-12-09 | 2002-09-24 | アムジエン・インコーポレーテツド | 神経栄養因子grnf4 |
CN1547483A (zh) * | 2000-12-22 | 2004-11-17 | �����ɷ� | Artemin-gdnf配体家族的一个成员的新用途 |
CZ20032080A3 (cs) * | 2001-02-01 | 2003-10-15 | Biogen, Inc. | Varianty neublastinu, fúzní polypeptid obsahující variantu neublastinu a farmaceutická kompozice obsahující neublastin pro léčení poruch nervového systému |
-
2002
- 2002-02-28 AT AT02719102T patent/ATE526982T1/de not_active IP Right Cessation
- 2002-02-28 CN CN028104978A patent/CN1525866B/zh not_active Expired - Fee Related
- 2002-02-28 EP EP02719102A patent/EP1395279B1/de not_active Expired - Lifetime
- 2002-02-28 NZ NZ529126A patent/NZ529126A/en not_active IP Right Cessation
- 2002-02-28 ES ES02719102T patent/ES2374971T3/es not_active Expired - Lifetime
- 2002-02-28 JP JP2002576995A patent/JP4499362B2/ja not_active Expired - Fee Related
- 2002-02-28 AU AU2002250203A patent/AU2002250203B2/en not_active Ceased
- 2002-02-28 CA CA2442159A patent/CA2442159C/en not_active Expired - Fee Related
- 2002-02-28 WO PCT/US2002/006388 patent/WO2002078730A2/en active Application Filing
- 2002-03-11 AR ARP020100876A patent/AR033031A1/es unknown
- 2002-03-26 MY MYPI20021081A patent/MY143470A/en unknown
-
2004
- 2004-07-29 HK HK04105615.0A patent/HK1062805A1/xx not_active IP Right Cessation
-
2008
- 2008-12-01 JP JP2008306855A patent/JP2009161515A/ja not_active Withdrawn
-
2012
- 2012-05-21 JP JP2012115400A patent/JP2012167119A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP4499362B2 (ja) | 2010-07-07 |
CN1525866A (zh) | 2004-09-01 |
NZ529126A (en) | 2010-07-30 |
JP2012167119A (ja) | 2012-09-06 |
CA2442159C (en) | 2011-08-23 |
MY143470A (en) | 2011-05-31 |
JP2009161515A (ja) | 2009-07-23 |
ES2374971T3 (es) | 2012-02-23 |
CA2442159A1 (en) | 2002-10-10 |
CN1525866B (zh) | 2013-05-29 |
AU2002250203B2 (en) | 2006-08-10 |
WO2002078730A2 (en) | 2002-10-10 |
EP1395279B1 (de) | 2011-10-05 |
AR033031A1 (es) | 2003-12-03 |
EP1395279A2 (de) | 2004-03-10 |
JP2005508842A (ja) | 2005-04-07 |
HK1062805A1 (en) | 2004-11-26 |
WO2002078730A3 (en) | 2003-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE288748T1 (de) | Verwendung von retigabin zur behandlung von neuropathischen schmerzen | |
ATE526982T1 (de) | Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen | |
ATE419856T1 (de) | Verwendung von rimexolon zur behandlung von augentrockenheit | |
ATE365042T1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
ATE456375T1 (de) | Verwendung von botulinum toxin zur behandlung von neuralgischen schmerzen | |
ATE308364T1 (de) | Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen | |
ATE452642T1 (de) | Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen | |
ATE257013T1 (de) | Verwendung von botulinum-toxin zur behandlung von diabetes | |
ATE534379T1 (de) | Neue verwendung von peptid-verbindungen zur behandlung von muskelschmerzen | |
DE60232400D1 (de) | Mittel zur linderung von hautreizungen | |
DE60123238D1 (de) | Zusammensetzungen zur behandlung von autoimmunkrankheiten | |
DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
DE60238765D1 (de) | Carbamatverbindungen zur behandlung von schmerz | |
ATE218862T1 (de) | Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen | |
DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
ATE380558T1 (de) | Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten | |
DE60026644D1 (de) | Verwendung von Ferulasäure zur Behandlung von Bluthochdruck | |
DE60223707D1 (de) | Calcium-l-threonat zur behandlung von knochenfrakturen | |
ATE404203T1 (de) | Verwendung von desoxypeganin zur behandlung der klinischen depression | |
DE60117122D1 (de) | Verwendung von mirtazapin zur behandlung von schlafstörungen | |
ATE465728T1 (de) | Verwendung von endothelin antagonisten zur behandlung von knochenkrebs und damit verbundenen schmerzen | |
ATE376416T1 (de) | Verwendung von ambroxol zur behandlung von chronischen schmerzen | |
DE60105053D1 (de) | Zusammensetzungen zur behandlung von gewebe | |
ATE226440T1 (de) | Zusammensetzung zur behandlung von psoriasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |